XM does not provide services to residents of the United States of America.
A
A

Ackermans

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Ackermans & Van Haaren On Track For FY Net Profit Above EUR 400 Mln

BRIEF-Ackermans & Van Haaren On Track For FY Net Profit Above EUR 400 Mln Nov 22 (Reuters) - Ackermans & Van Haaren NV ACKB.BR : ON TRACK TOWARDS NET PROFIT FOR FY 2024 THAT IS WELL ABOVE 400 MILLION EUROS MAINTAINS END-SEPT ROBUST NET CASH POSITION OF 294.8 MILLION EUROS Source text: ID:nGNE6dZF8K Further company coverage: ACKB.BR (Gdansk Newsroom
A

AJ Bell, Frequentis AG, Sage Group

EUROPE RESEARCH ROUNDUP-AJ Bell, Frequentis AG, Sage Group Nov 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AJ Bell, Frequentis AG and Sage Group on Thursday. HIGHLIGHTS * AJ Bell AJBA.L : Jefferies raises target price to 530p from 485p * Crest Nicholson Holdings Plc CRST.L : Berenberg cuts PT to 195p from 215p * Frequentis AG FQT.DE : Berenberg initiates coverage with buy rating; PT EUR 33 * Sage Group SGE.L : Jefferies rais
A
B
B
C
E
F
K
L
L
M
N
R
R
S
S
S
W
Z
A
I
J
S

French and Benelux stocks-Factors to watch on Nov 21

French and Benelux stocks-Factors to watch on Nov 21 Nov 21 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. Ackermans & Van Haaren ACKB.BR : Belgian holding company and the Delen family extended historic shareholder agreements for 25 years. Exclusive Networks EXN.PA : French cybersecurity company said CD&R and Permira had obtained all regulatory clearances necessary for the closing of the prop
A
S
F
N
U

Ackermans & Van Haaren, Delen Family Extend Historic Shareholder Agreements For 25 Years

BRIEF-Ackermans & Van Haaren, Delen Family Extend Historic Shareholder Agreements For 25 Years Nov 21 (Reuters) - Ackermans & Van Haaren NV ACKB.BR : CO AND DELEN FAMILY CONFIRM THEIR LONG-TERM PARTNERSHIP WITH UPDATED SHAREHOLDER ARRANGEMENTS IN RESPECT OF DELEN PRIVATE BANK AND BANK J. VAN BREDA & CO EXTENDING THEIR AGREEMENTS FOR 25 YEARS DELEN
A

AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments

UPDATE 7-AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments Q3 revenue and core EPS beat estimates AstraZeneca announces $3.5 billion US investment CEO says growth looks set to continue through 2025 Shares down as market focuses on co's China issues AstraZeneca's China chief in custody, company doesn't know why Updates shares in paragraph 8, investor and analyst comments on share drop in 9- 11 By Maggie Fick and Yadarisa Shabong Nov 12 (Reuters) - Drugmaker AstraZeneca
A
A
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.